Emerging Healthcare Landscape of India:

Emerging Healthcare Landscape of
IndiaExecutive Summary
April 2018
Amsterdam Copenhagen Hamburg Mumbai New York Oslo Singapore Stockholm
2018 Universal Consulting India Pvt Ltd. All Rights Reserved.©Copyright

Contents
 Country Context
 Regulatory Changes
 Pharmaceuticals
 Medical Technology
 Diagnostics
 Institutions
 Digital Health
 Conclusion

Governance and Healthcare Index
Source: Healthcare Access and Quality Index 2015: Global Burden of Disease Study, 2015, Lancet Report; : Worldwide Governance Indicators, 2014: World bank,
http://databank.worldbank.org/;
India

Access Challenge
Source: Urban Population Contribution To National GDP To Touch 70% By 2011, The Associated Chambers of Commerce and Industry of India, March 2008, Census 2011 (accessed 3
February, 2015), UN – World Urbanization Prospects (The 2014 Revision)
77.0%
539mn.
74.0%
621mn.
72.0%
734mn.
68.0%
896mn.
50.0%
805mn.
23.0%
161mn.
26.0%
219mn.
28.0%
286mn.
32.0%
429mn.
50.0%
814mn.
0%
20%
40%
60%
80%
100%
1981-1990 1991-2000 2001-2010 2011-2020 E2050
Population
%
Rural
Urban

Affordability Challenge
Source: National Council for Economic Research (India), Ministry of Health and Family Welfare, CDSCO website
0
50
100
150
Urban Rural
0.6
10.2
1.0
7.3
Number of Households in Mn.
(2014)
18.1
107
57
.5
60.7
87 Mn
176 Mn
Lowest income (< USD 1,800 p.a.)
Lower income (USD 1,800 – 4,000 p.a.)
Middle Income (USD 4,000 – 20,000 p.a.)
Upper Income (>USD 20,000 p.a.)

National Health Protection Scheme (2018)
Source :http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2015;volume=142;issue=4;spage=383;epage=390;aulast=Nandi
Notes : ** The evidence for the impact of RSBY are unclear due lack of administrative data on various aspects of the scheme
The NHP was last reformed in 2017, however it needed to be amalgamated with an insurance scheme
• INR 500,000 cover per family
• Existing disease covered
• Pre and post hospitalization expenses covered
• Coverage of 10mn families based on SECC data
• No cap for family size and age
• Defining package rates for surgeries
• Management of funds
• Preventing system leakages
• National roll out
• Providers adherence to the scheme
• Y-O-Y expenditure expected to increase up to 15%
for 5 years
National
Health Policy
2002 2005
National Rural
Health Mission
2008
Rashtriya Swasthya
Bima Yojana (RSBY)
2018
National Health
Protection scheme
-486 districts (28 States and Union
Territories) covered until 2012
-Settlement of 175Mn cases by 2013
-Increase in individuals covered
from 4Mn in 2009 to 34Mn in 2013
- Service offerings from 15
insurance companies, 25 TPAs
-12,000 hospitals empaneled
Even with irregularities, RSBY led to
Focused needs of
under-served rural
areas
Unifying frame-
work
Coverage of below the
poverty line, larger scheme
, larger fund allocation
Higher fund allocated for
insurance, Higher
population coverage
- Integration of existing policies absent
- Decentralized service delivery
- Focus on states that lag health
indicators
- Unclear evidence to
examine the impact of
RSBY**
- Scheme considered to
be underfunded
- Systemic leakage
- Insurance frauds
- Inadequate
reimbursements
Evolution of the existing health policy scheme in India
Key Questions:
- Contours of the scheme
- Implementation
- Actual allocation of funds
- Infrastructural
development
- Dedicated medical
fraternity
- Adequate drugs and
supplies
ChallengesBenefits
2009 - 2017
Benefits Challenges

73%
27%
0%
20%
40%
60%
80%
100%
Public Vs Pvt
Health Insurance Challenge
Health Insurance Density (2015)
%
Note: *NHPS means National Health Protection Scheme;
Source: IRDA Annual Report, 2014 - 15, Hindustan times – 17 Oct. 2017, India spend – 07 June 2017, The astonishing cost of healthcare in India, Quartz India, 18th April, 2016, Economic
Times – 10th Oct 2017, UC Analysis
994mn
314mn
0%
20%
40%
60%
80%
100%
Insurance Density
Private
Insurance
Public
Insurance
Insured
Not
Insured
Health Insurer (2015)
*NHPS aims to
address this issue

1.1% 1.4%
4.2%
3.1% 3.7% 3.8%
7.6% 8.3%
1.8%
3.3%
1.2% 2.5%
3.4%
4.5%
1.5%
8.9%
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
Indonesia India Turkey China Russia Brazil United
Kingdom
United
States
Low Public Spending
Source: World Bank, WHO (accessed 19th October 2017)
(in USD Bn.)
Public
Private
Healthcare Spend as % of GDP (2014)
2.8%
4.7%
5.4% 5.5%
6.3%
7.1%
8.3%
9.1%
17.1%
*NHPS aims to
address this issue

High OOPE
OOPE % of Total Health Expenditure (2014)
9.7% 11.0%
17.8%
25.5%
32.0%
44.0% 45.8% 46.9%
62.4%
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
United
Kingdom
United
States
Turkey Brazil China Mexico Russia Indonesia India
Source: WHO, World Bank Data
*NHPS aims to
address this issue

Contents
 Country Context
 Pharmaceuticals
 Diagnostics
 Institutions
 Digital Health
 Conclusion

38%
39%
5%
18%
0%
20%
40%
60%
80%
100%
2015
131
226
-
50
100
150
200
250
2016 2020
Indian Healthcare Sector
Source: WHO, World Bank Data
Note :1. Indicated split is representative contribution of key healthcare segments to overall healthcare market. Healthcare services does not include primary
healthcare services. There is certain proportion of primary healthcare provided by the state which has not been included/ estimated
2. The pharma segment accounts for the formulations and API, domestic as well as global market
Pharma
Healthcare services
By Segments %
Medtech
Others
USD Bn
CAGR
(2016 – 20)
- 14%

Source: Previous UC Engagements, Hindu BusinessLine – “Stent prices slashed by 85%; health group gives thumbs up”, Indian Express – “US firms approach USTR against India’s medical
price control measures”, Economic times – “Now, government plans to cap margins of medical devices to bring down prices”, Times of India – “To market new drugs in India, global trials must
include Indians”
Regulatory Landscape Flux
Impact of Impending Regulations
Multiple sub-committees under Ministry of Health working independently to establish
policies/regulations
Regulation Remarks
Essentiality
• National list of Essential Medicines
• National list of Essential Medical Devices
Price Capping/
Control
• ~85% and ~69% price caps for stents and knee implants respectively
• USTR against India`s medical pricing steps
Local Manufacturing
• NMDP - ‘Make in India’
• 100% FDI permitted, fallen to 50% as of 2017
• Import duties hike for raw materials vs semi-finished goods
Trade Margin Capping
• DoP categorizing 23+ devices for limiting trade margins
• Method favored by Medical Technology Association of India
Clinical Trials; Indian
samples
• New drugs developed outside the country, should include Indian patients in the global
clinical trials
Genericization
• Mandatory Generics Prescriptions
• Propagation of Jan Aushadhi Scheme
National Health
Protection Scheme
• Special focus on TB
• Limitations for MNC products in public hospitals
• Increase influence of private insurance industry in the public healthcare space

Contents
 Country Context
 Pharmaceuticals
 Diagnostics
 Institutions
 Digital Health
 Conclusion

Pharma Market
15.4
23.3
0
5
10
15
20
25
2016 2020
CAGR - 11.0%
Indian Pharma Market
In USD Billion
13.9
1.6
1.5
-
2
4
6
8
10
12
14
16
18
2017
Market segmentation
In USD Billion
17
Note: 1 – Fixed dose combinations (FDC), 2 - Unbranded generics market share has been derived by deducting the share of branded generics from total
market, 3- The market size indicates India market (consumption) and excludes exports
6.8
10.2
-
2
4
6
8
10
12
14
16
18
2017
FDC penetration
In USD Billion
17
Source: Primary Research, Indian pharmaceutical industry, India Brand Equity Foundation, 2017, Generics to double in 5 years, The Hindu, 12th Sept, 2015
Unbranded
generics
Branded
generics
Patented
Non - FDC
FDC

Genericization (Gx)
Source: Indian pharmaceutical industry, Times of India – 18 Apr 2017, The wire – 1 May 2017, Jan Aushadhi, Drugs and Control act, Drugs and Cosmetics act
• Medical Council of India 2016 circular mandates physicians to Rx drugs with
generic names
• Govt. propagating affordable generics via Jan Aushadhi scheme
• Pharma companies to conduct BE tests for certain generics and print labels with
generic names 2X brand names
• Stakeholders have concerns about implementing the policy while maintaining
drug quality

Gx: Supplementary Policies Required
India US UK Germany Finland Sweden France
Main
Policies
Generic
Prescription
Generic
Substitution
Supplementarypolicies
Regulated
Pricing
Physician
Incentives
Pharmacist
incentives
Formulary
Mandated Not Mandated
or Supported
Source: Primary Research, The experiences of implementing generic medicine policy in eight countries, Saudi Pharmaceutical Journal, 2014, European market entry strategy for generic
companies, European Commission,2016, Pharmering markets – Picking a pathway to success, IMS Health, 2013

1.5
3.6
13.9
17.5
1.6
2.1
0
5
10
15
20
25
2017 2020
11.0%
8.0%
33.1%
If Public Sector Shifts To Gx (15%)
(Bn USD)
9.0%
15.5
%
81.8
%
75.3
%
9.2% 9.2%
0%
25%
50%
75%
100%
2017 2020
%
17
23.2
11.1
6.0
-
5
10
15
2017
17
(Bn USD)
Note: Overall contribution of public sector by value is expected to go down
Source: Primary Research, UC Analysis
CAGR
‘17 – ‘20
Public
sector
Private
sector
Unbranded
generics
Branded
generics
Patented
Unbranded
generics
Branded
generics
Patented

1.5
4.9
13.9
16.2
1.6
2.1
0
5
10
15
20
25
2017 2020
14.
1
2.9
-
4
8
12
16
20
2017
11.0%
5.2%
47.6%
If NLEM Shifts To Gx (21%)
9.0%
21.2%
81.8%
69.7%
9.2% 9.2%
0%
25%
50%
75%
100%
2017 2020
%
17
23.2
17
CAGR
‘17 – ‘20
Unbranded
generics
Branded
generics
Patented
Unbranded
generics
Branded
generics
Patented
NLEM
Non - NLEM
(Bn USD) (Bn USD)

Gx Impact
Facilitators Probability
Global
MNC
Large
Domestic
*
Small
Domestic
#
Rationale
Stringent
Quality
Regulations
High • High Cost of BA/BE studies
Acceptance By
Healthcare
Professionals
Medium • Physicians propagate MNC generics
Adoption Of
Generics
Across Govt.
And Private
Institutes
Medium
• Adoption likely in govt. institutes only
Increase In
Generic
Acceptance
Among
Patients
Medium
• Physicians influence Patients'
acceptance
Note: * Large Domestic Players – Players contributing >0.5% to Indian Pharma Market, # Small Domestic Players – Players contributing to <0.5% to Indian Pharma Market
Favorable Not Favorable

Industry Dynamics
Note; * Width of the bar indicates the number of players in this space
Current Scenario* Post Genericization**
Small Domestic
Players
Large Domestic
Players
Global MNC’s
Global MNC’s
Large Domestic
Players
Small Domestic
Players

Reassess
Manufacturing
Strategy
Reorganize
Sales Strategy
Prioritize
Institutional
Segment
Four Genericization Strategies
Expand
Product
Portfolio
Source: UC Analysis
• OTC
• Ayurvedic products
• Differentiated
formulations
• Direct selling to
institutions
• Digital marketing
• Updated training
programs
• Revised
performance
metrics
• Cost effective
manufacturing
option w/o
compromising
quality
1 2 3 4

OTC
2.4
5.0
0
1
2
3
4
5
6
2016 2020
CAGR (‘16-’20)
- 20%
OTC Industry (USD Bn.)
0.55
1.83
0
1
2
3
4
5
6
2016 2020
Dietary Supplement Industry (USD Bn.)
Limited price controlHigher growth
Source: A brief report on nutraceutical products in India, ASA and Associates, 2015
CAGR (‘16- ‘20)
- 35%

Pharmaceutical companies
Ayurveda
23.5
23.6
26.1
27.1
30.3
31.1
32.8
37.1
37.6
38.4
41.3
43.3
50.5
52.6
74.4
0 20 40 60 80
Digene
Band-Aid
Benadryl
Pudin Hara
Halls
Unwanted 72
Iodex
i-pill
Himani
Vicks
Moov
Volini
Zandu
Hajmola
Eno
OTC brands ranked by sales – FY’16
(USD Mn.)
FMCG companies
Source: Euromonitor data - 2016
Ayurveda
Company
Branch of
medicine
GSK Ayurveda
Dabur Ayurveda
Zandu Ayurveda
Sun Pharma Allopathy
Paras Pharma
Ayurveda
P&G
Ayurveda
Zandu
Ayurveda
Piramal Allopathy
GSK
Ayurveda
Mankind Allopathy
Mondelez
Dabur Ayurveda
J&J Allopathy
J&J NA
Abbott Allopathy
Ayurveda
Allopathy
Gastrointestinal
Lifestyle
Cough, cold and allergy
Emergency contraceptives
Analgesics
Therapy Area

OTC: Three Levers to Win
Explore New
Channels
Ranbaxy and Pfizer’s tie-
up with ITC to improve
OTC rural reach
Evaluate Marketing
Spend
About 16-19% of
revenues spent on
marketing Eno, Himani
and Vicks
Establish Rx to OTC
Engine
Boehringer Ingelheim`s
Dulcoflex and Buscogast
success in OTC market,
addressing unmet needs
Source: Glaxo SmithKline Annual Report, 2016, Emami Annual Report, 2016, Procter and Gamble Annual Report, 2016

Contents
 Country Context
 Pharmaceuticals
 Diagnostics
 Institutions
 Digital Health
 Conclusion

MedTech Sector - Implants
70
60
80
30
40
20
0%
20%
40%
60%
80%
100%
Cardio Ophthal Ortho
Local
MNC
MNC Vs Local (2015)
%
770
1260
410
490
260
500
0
500
1000
1500
2000
2500
2015 2020
Implants Market – Key Therapy
Segments* (USD Mn)
Cardiology
Ophthalmology
Orthopedic
CAGR
14%
10%
4%1440
2250
Note: *Not exhaustive
Source: Previous UC Engagements, AIMED, UC Analysis

MedTech Evolution - ImplantsPhas
e
Status Quo – MNCs build
the market
Rise of indigenous players
SalientTrends
Emergence of Market
Leaders
Source: Medical Devices Growth in Emerging Markets, Lessons from other industries (IN VIVO: The Business & Medicine Report)
Dominance by MNC’s
Technological
advancement
Enhanced research and
development
Favorable govt.
regulations
Conducive local
manufacturing
ecosystem
Market gap filled by
economy players
Underserved market
Market Leaders:
Indigenous Players
• Develop high quality products
• Work in partnership with MNCs for
technical superiority
Market Leaders: MNC
• Launch innovative products
• Work with the distribution network
of the local players
• Tie-up with local manufacturers
• Unequalled quality MNC
products
• Limited indigenous players
Indigenous players start
manufacturing high quality
products
Increased share of value
players
Phase 1 Phase 2 Phase 3

Rising demand from price
sensitive tier 2,3 markets
Value Segment
Percutaneous
Coronary
Intervention Market
Total Knee
Replacement
Market
69% 52%
Intra-Ocular Lens
Market
48%
Overall market CAGR :
10%
Value segment CAGR :
12%
Overall market CAGR : 3.7%
Value segment CAGR : 6.8%
Overall CAGR :
18%
Note: Figures mentioned inside the circle represent value segment market share
IOL- Intra-Ocular Lenses; PCI - Percutaneous Coronary Intervention (commonly known as Angioplasty) ; TKR – Total Knee Replacement
Assumption - Tier 1 cities mainly consists of premium products and Tier 2 cities mainly consists of value products
Source: Previous UC Engagements
- Premium - Value - Economy
- Economy + Value - High Value + Premium
2016 Market Shares
Legend
Improved clinical data availability Feature focused market

MedTech: MNC Value Trap
BlindsidedUnaware Underestimate
Source: UC Analysis, Previous UC Engagements
Fear Disregard Inflexible

MedTech: Six Levers To Win
Evaluate
Value
Segment
Develop 3-
Tiered Pricing
Approach
Manage Key
Accounts
Local
Manufacturin
g
Penetrate
Lower Tier
Geographies
Assess
Inorganic
Opportunities

Contents
 Country Context
 Pharmaceuticals
 Diagnostics
 Institutions
 Digital Health
 Conclusion

84
65
118
82
0
20
40
60
80
100
120
Diabetes
Prevalence
CHD
Prevalence
3 2
14
44
4
2
18
54
0
10
20
30
40
50
60
TB HIV HCV HBV
Hyper
tension
Heart
Disease
Diabetes
Hepatitis B
Others
Disease burden (2014)
%
Chronic & Infectious Disease Burden
Source: WHO, AVERT.org, tbfacts.org, Viral hepatitis eradication in India by 2080 - gaps, challenges & targets, IJMR, UC Analysis
35
%
30
%
18
%
12
%
5%
0%
20%
40%
60%
80%
100%
Disease
Burden
Growth in chronic
disease
In Millions
Growth in infectious diseases
In Millions
2016-20
CAGR-
9%
CAGR-
6%
CAGR- 8%
CAGR- 2%
CAGR- 8%
CAGR- 5%
2016-20 2016-20 2016-202016-20 2016-20

Diagnostic Market
Source : UC Analysis, Previous UC Engagements, http://www.business-standard.com_July 2014, Forbes Magazine_March 2015, Economic Times_2015, LiveMint, http://trak.in/
india-startup-funding-investment-2015, http://health.economictimes.indiatimes.com/health-files/2015-in-review-the-diagnostic-industry/1150
Diagnostics Market Size
0.3
0.8
1.9
3.0
0
1
2
3
4
2016 2020
2.2
3.8
Organized
25-30%
Unorganized
12%
Total
15%
USD Bn
CAGR
(2016-20)
0%
20%
40%
60%
80%
100%
2016
Molecular
Dx
Other
Pathology
~2-4%
~95%
National and Regional Lab
Chains – Volume Split by Type of
Tests%
CAGR
(2016-20)
MDx
12%

Monitoring Challenge
Source: Live mint – “Lack of regulations still a concern for diagnostic laboratories industry”
NABL
Accreditation Not
Mandatory
Regulatory Grey
Zone
Highly
Fragmented
Market
• 5 national lab chains
(500+ collection
centres) to become 7
by 2020
• 15 regional lab chains
(100+ collection
centres) to become 20
by 2020
• ~70,000 stand alone
diagnostic laboratories
• Clinical
Establishment Act,
2010 by Centre
prescribes minimum
standards
• However, only
adopted by 10 states
• Health, a state matter
• NABL: nodal agency
for accreditation,
• Accreditation in India
not mandatory
• <2%(783) labs,
accredited till January
2017

Molecular Diagnostics
Source : UC Analysis, Previous UC Engagements
Demand for highly specialized tests (PGD, PGS and NIPT) has led to diagnostic labs
investing in high end technologies - Next Generation Sequencing and Microarrays
Example: New testing areas - Reproductive Health
• 15% out of 26 Mn+
annual pregnancies in India are
high risk
• 27MnInfertile
couples in India
• IVF specialists
promoting Pre-
natal
genetic
screening
successful implantation
• Pre-natal
genetic
screening
for community
specific
chromosomal
abnormalities
• 1.4/1000 incidence of
Downs Syndrome
• 0.28/1000
incidence of Edward’s
Syndrome
• 2-3%
congenital
malformations

Diagnostics: Five Levers to Win
Source: UC Analysis
Focus On
Regional Labs
Reach Out To
Doctors
Marketing To
Specialists
Customization of
Solutions e.g.
Panels
Shape and
Evangelize
Diagnostic
Pathways

Contents
 Country Context
 Pharmaceuticals
 Diagnostics
 Institutions
 Digital Health
 Conclusion

29.9
41.9
10.4
15.9
5.2
16.5
2.2
3.8
0
20
40
60
80
100
2016 2020
Healthcare Institution Segment
USD Bn
Upsurge of medical tourism
• CAGR of Medical tourism: 26%
• 150 countries eligible for medical visas
• ~2 mn medical tourists in 2016
Rise of single specialty healthcare
• Low setup cost; Rise in SSH
• Women and Child, Cardiology and Oncology form
45% of SSH
MSH
SS
H
Wellness
Diagnostics
48
78
Note: SSH – Single Specialty Hospital, MSH – Multi Specialty Hospital
Source: WHO, Annual Reports, KPMG, UC Analysis, Previous UC Engagements
Healthcare Services – Key Segments
CAGR (2016-20)
- 13%

E-pharmacy/ Retail Pharmacy
Source: Economic Times (Sep 15 2017) – “How online pharmacies are now rushing to pace up growth”, YourStory (21 Jun 2016) – “A nascent Indian e-pharma sector already plagued by bias and
harassment”, FICCI Report – “E-Pharmacy in India: Last mile access to medicines”
• Online pharmacy market ~ USD 110mn.
to USD 120 Mn
• Estimated 45-50 e-pharma start-ups in
India
Key challenges affecting regulatory
decisionsMarket dynamics
• Drug abuse
• Tracking consignments
• Inter-state selling
• 25 Chains aggregating to ~2000 outlets
• Less than 20% penetration across the
pharmacy retails
• Availability of qualified pharmacists
across outlets
Key challenges affecting regulatory
decisionsMarket dynamics
E-pharmacy
Retail Pharmacy

3.5 3.4
3.1
2.3
2
1.3
0
1
2
3
4
WHO* UK US Brazil China India
Infrastructure Rollout
Source: IBEF Sector Report, WHO
Healthcare infrastructure
In-patient beds/ 1000
Global average - 2.9
0.
3
3.
4
Rural
India
Urban
India
Note : * WHO Recommendation
Over USD 200 bn to be spent on medical
infrastructure by 2024
1.54 million doctors and 2.4 million
nurses required to match infrastructure
growth
Additional ~3 million beds to match
global average
Improved access to services in lower
tiered geographies e.g. Apollo, Fortis
Hospital

14.2
20.3
2.7
5.2
0
5
10
15
20
25
30
2016 2020
Hospital Retail
Institutional Segment
CAGR
(2016-20)
17%
9%
16.9
25.5
Pharmaceutical Sales by Channel
(USD Bn)
Increased adoption of unbranded
generics
Savings from hospital specific
unbranded generics
Infrastructure roll out in SSH, tier 2 etc.
Source: Primary Research, IMS health market reflection report, IMS Health, 2016, Healthcare industry in India, India Brand Equity Foundation, 2017, UC Analysis
Increased relevance of purchase
committee

Institutions: Four Levers to Win
Partner with
Institutions
for Capability
Building
Develop a
Marquee
Account
Strategy
Expand into
Lower Tier
Geographies
Leverage E-
pharmacy and
Retail Chain
Growth

Contents
 Country Context
 Pharmaceuticals
 Diagnostics
 Institutions
 Digital Health
 Conclusion

Digital Healthcare
Note: a) Market size does not include e-pharmacy b) Health and Wellness Analytics include consumer related analytics and may have an overlap with data analytics performed for enterprises
such as with Big Data
Source: Deloitte Analysis, Gartner, NASSCOM: India Health-tech products report
50%
23%
17%
8%
2%
0%
20%
40%
60%
80%
100%
2015
Administrative
and Management
Software
Mobile Apps
Healthcare Platforms
Health and Wellness
Analytics
Wearables
India Healthcare Software Market by Segment Some Players
Wearables
Health and
Wellness
Analytics
Healthcare
Platforms
Mobile Apps
Administrative
and
Management
Software

Digital Strategy: Three Levers to Win
Evaluate
E-Detailing
Customize
Digital
Strategies for
Specific
Therapy
Areas/Marquee
Accounts
Establish
Digital Reach
with
Caregivers,
Clinicians and
Patients

Contents
 Country Context
 Pharmaceuticals
 Diagnostics
 Institutions
 Digital Health
 Conclusion

Conclusion
Large GDP; Low
per Capita
Income
4.7% of GDP
Spend
154th
on
Healthcare
Index
900+Mn
Uninsured
Financial
InclusionFocus
Price Caps -
2017
Gx:
Genericization
Policy
Gx:Pharma
Consolidation
Gx:Strategy
Modification
OTC/Ayurveda
Growth
MedTech Value
Segment
Emergence
Advanced
Molecular
Diagnostics
Specialty/
Medical Tourism
Growth
Institutional
Segment
Growth
E-pharmacy/
Retail Growth
Healthcare
Digitisation
Tier 2
Healthcare
Penetration
Overview
Pharma
Healthcare
Services
MedTech
Diagnostics
Digitisation
National Health
Protection
Scheme - 2018
Healthcare Landscape – Key Elements Legend

AMSTERDAM
QVARTZ
Piet Hein Buildings – Wit, 8e etage
Piet Heinkade 95a, Amsterdam
Netherlands +31 6 11000204
HAMBURG
QVARTZ
Neuer Wall 40, DE-20354
Hamburg, Germany +49 40 298 13 470
NEW YORK CITY
QVARTZ
1185 Ave. of the Americas, 3rd floor, Suite 213
New York, NY 10036, USA +1 646 492 9913
SINGAPORE
QVARTZ
One George Street, Level 10-01
Singapore 049145 +65 91 59 94 17
COPENHAGEN
QVARTZ
Ryesgade 3A, DK-2200
Copenhagen N, Denmark +45 33 17 00 00
MUMBAI
UNIVERSAL CONSULTING INDIA PVT LTD
Shivsagar Estate D
Dr Annie Besant Road, Worli
Mumbai 400018, India +91 22 66222100
OSLO
QVARTZ
Wergelandsveien 21, NO-0167
Oslo, Norway +47 22 59 36 00
STOCKHOLM
QVARTZ
Birger Jarlsgatan 7, SE-111 45
Stockholm, Sweden +46 (0)8 614 19 00
If you would like to schedule a meeting to discuss this document, please email us at strategy@universalconsulting.com

UNIVERSAL CONSULTING INDIA PVT LTD
Shivsagar Estate D, Dr Annie Besant Road
Worli, Mumbai 400018, India
+91 22 66222100
strategy@universalconsulting.com
www.universalconsulting.com
241
994-2018
Amsterdam Copenhagen Hamburg Mumbai New York Oslo Singap

Emerging Healthcare Landscape of India:

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Emerging Healthcare Landscape of India:

Similar to Emerging Healthcare Landscape of India: (20)

More from UC STRATEGY (Universal Consulting India Pvt Ltd)

More from UC STRATEGY (Universal Consulting India Pvt Ltd) (20)

Recently uploaded

Recently uploaded (20)

Emerging Healthcare Landscape of India: